Introduction
Neurological disorders have been reported in approximately 40% of adult AIDS patients [11, 22] . However, up to 70%-80% of adult AIDS patients have been shown to have neuropathological abnormalities in autopsy-based surveys [14, 19] . The most frequent and most important cause of neurological morbidity in HIV-infected patients is HIV encephalopathy [7] . There is increasing evidence that this disorder, which has also been referred to as subacute encephalitis [17, 19] or AIDS dementia complex [15, 16, 20] , is caused by direct HIV brain infection. The white matter and subcortical structures of the Offprint requests to." H. W. Pfister cerebral hemispheres are most severely involved with relative sparing of the cortex [8, 14, 18, 19] . The major pathological abnormalities are infiltrates of macrophages and multinucleated giant cells and microglial nodules. Involvement of the white matter appears either as diffuse leucoencephalopathy with severe loss of myelin or as small paravascular loci of demyelination [5, 8, 10, 16] . De la Monte et al. [5] reported demyelination in 44% of autopsy cases with HIV encephalopathy.
Elevated myelin basic protein (MBP) levels within the cerebrospinal fluid (CSF) provide a marker for central nervous system demyelination, as has been shown in patients with relapsing-remitting multiple sclerosis [3, 13, 24] . The purpose of the present study was to investigate if CSF MBP has a role as a useful and early marker for HIV encephalopathy. We investigated CSF samples of 40 consecutive patients with HIV infection of various clinical stages, including 13 with clinical signs of HIV encephalopathy.
Patients and methods
Seven of the HIV-positive persons were clinically healthy (stage WR 1), 22 suffered from the lymphadenopathy syndrome or the AIDS-related complex (WR 2-5) and 11 had full-blown AIDS (WR 6). Clinically manifest HIV encephalopathy was diagnosed in 13 patients. Symptoms of mental deterioration (n = 11) and/or pontomesencephalic or cerebellar dysfunction (n = 4) were used as diagnostic criteria (Table 1) . Opportunistic conditions, including both infections and neoplasms, were not evident in these 13 patients with HIV encephalopathy.
CSF and serum samples were collected from 40 HIV-positive patients. Oligoclonal IgG bands were detected by isoelectric focusing. The samples were concentrated and run on a polyacrylamide gel at a pH gradient of 3-9 (Phast-System; Pharmacia, Uppsala, Sweden). The gels were stained with Coomassie blue. The ratio CSF albumin/serum albumin was used as an indicator of blood-CSF-barrier permeability. A commercial ELISA was used to determine IgG antibody titres to HIV. A CSF/serum quotient of IgG-related HIV antibodies above 1.5 was considered to indicate intrathecal production of HIV antibodies [12] . MBP in CSF was determined using a commercial, competitive radioimmunoassay (Biodata; Milan, Italy). Fifty microlitres of a histone solution (2.5 ng/ml) was added to 500 gl flesh CSF sample to prevent adhesion. The samples were stored at -1 8°C until they were analysed. The reference range for M B P in CSF was defined as follows: up to 3.4 ng/ml, normal; 3.4-4.6 ng/ml, marginal; and above 4.6ng/ ml, elevated.
Results

CSF abnormalities were detected in 32 patients (80%).
Oligoclonal IgG bands were found in the CSF of 29 patients (73%); 18 of 24 patients with oligoclonal IgG bands in the CSF had evidence of intrathecal H I V antibody production.
Lymphocytic pleocytosis ranging from 5 to 146 cells/btl was present in 17 patients and an elevated ratio of CSF albumin/ serum albumin (> 7.5) in 8 patients. CSF MBP was elevated in two patients (5.0 and 5.3 ng/ml), both suffering from full-blown AIDS. One of these patients presented with severe dementia and a history of oesophagitis.
The other patient had a history of Pneumoc~stis carinii pneumonia and presented with moderate dementia and severe myelopathy which could not be attributed to any condition other than HIV infection. Neurological symptoms had progressed rapidly over a few months in both patients. In the remaining 38 patients, CSF MBP levels were marginally elevated (n = 12) or normal (n = 26). There was no significant correlation between elevated (including marginally elevated) CSF MBP levels and intrathecal HIV antibody production, oligoclonal IgG bands, or lymphocytic pleocytosis (chi-square test, P > 0.05).
Discussion
Elevated levels of CSF MBP secondary to acute myelin breakdown are present in many patients with active disease of the nervous system, e.g. multiple sclerosis, tranverse myelitis, central pontine myelinolysis [3, 25] . In the current study elevated MBP CSF levels were detected in only 2 patients, both of whom presented with moderate to severe HIV encephalopathy. In the other 11 patients with HIV encephalopathy as well as in 27 HIV patients without clinically apparent HIV encephalopathy, only marginally elevated or normal MBP levels were found. There was no significant correlation between CSF MBP levels and intrathecal HIV antibody production. Our resuits suggest that CSF MBP is not a sensitive marker for the diagnosis and evaluation of HIV encephalopathy.
The rapidity of demyelination seems to influence MBP levels in the CSF, as is known from studies in multiple sclerosis [2, 4, 13] . In multiple sclerosis elevated MBP was usually detected in the CSF of patients during acute exacerbations of the disease. MBP was not detected in the CSF of any patient with a slowly progressive form of multiple sclerosis. It was speculated that in slowly progressive demyelination CSF MBP might be degraded by macrophages or proteinases or inactivated by antibodies, thus preventing elevation of MBP [1, 6, 13, 21, 23] . The rare finding of elevated CSF MBP levels in patients with HIV encephatopathy in the current study may be explained by the fact that the disorder is more often chronically progressive than subacute in its evolution [20] . It must be stressed that in the current study the clinical course of HIV encephalopathy in the 2 patients with elevated CSF MBP levels differed from that of the other patients with HIV encephalopathy in that both suffered rapidly progressive dementia. Since CSF MBP is elevated in acute exacerbations of multiple sclerosis as well as in rapid progressive cases of HIV encephalopathy, we think that an elevated CSF MBP level may be a prognostic marker for the course of HIV encephalopathy. Previous studies in patients with other neurological diseases have shown that CSF MBP is not a specific marker. Other neurological disorders affecting the CNS in HIV-infected patients, such as progressive multifocal leucoencephalopathy [25] or herpes simplex encephalitis [9] , may also cause elevated CSF MBP levels. Furthermore, combinations of HIV encephalopathy and opportunistic infections may occur, which complicate the interpretation of elevated CSF MBP levels.
We conclude that CSF MBP is not a sensitive marker for HIV encephalopathy. The significance of normal and marginally elevated CSF MBP levels with respect to demyelination is unknown. Elevated CSF MBP levels may indicate a rapidly progressive course of HIV encephalopathy provided that other CNS disease is not present.
